- Home
- VRCA vs SKIN Comparison
VRCA vs SKIN Comparison
Compare VRCA & SKIN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | VRCA | SKIN |
|---|---|---|
| Founded | 2013 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Package Goods/Cosmetics |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 107.5M | 117.4M |
| IPO Year | 2018 | 2020 |
Fundamental Metrics
Financial Performance| Metric | VRCA | SKIN |
|---|---|---|
| Price | $5.54 | $0.84 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 4 |
| Target Price | ★ $17.00 | $2.03 |
| AVG Volume (30 Days) | 36.0K | ★ 6.0M |
| Earning Date | 05-11-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 55.56 |
| EPS | N/A | ★ N/A |
| Revenue | $35,577,000.00 | ★ $300,790,000.00 |
| Revenue This Year | N/A | $0.88 |
| Revenue Next Year | $94.44 | $4.60 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 370.22 | N/A |
| 52 Week Low | $3.28 | $0.55 |
| 52 Week High | $9.82 | $2.69 |
Technical Indicators
Market Signals| Indicator | VRCA | SKIN |
|---|---|---|
| Relative Strength Index (RSI) | 40.43 | 54.36 |
| Support Level | $5.32 | $0.81 |
| Resistance Level | $6.60 | $0.92 |
| Average True Range (ATR) | 0.47 | 0.12 |
| MACD | -0.07 | 0.00 |
| Stochastic Oscillator | 22.10 | 36.54 |
Price Performance
Historical ComparisonAbout VRCA Verrica Pharmaceuticals Inc.
Verrica Pharmaceuticals Inc is a therapeutics company developing and commercializing medications for the treatment of dermatologic diseases, including skin cancers. Its commercial product and portfolio of product candidates are clinician administered therapies in areas of high unmet need. This product portfolio consists of one product with an approved indication for molluscum contagiosum, or molluscum, with the potential for several follow-on indications, as well as additional pipeline product candidates. Its commercial product, YCANTH (VP-102), for the treatment of molluscum in adult and pediatric patients two years of age and older. YCANTH (VP-102) is a proprietary drug-device combination that contains a GMP-controlled formulation of cantharidin.
About SKIN The Beauty Health Company
SkinHealth Systems Inc is a world-wide medical aesthetics company delivering an integrated ecosystem of clinically validated solutions designed to help consumers achieve superior skin health and support the success of providers. Its brands are Hydrafacial and SkinStylus.